公开(公告)号：US20190314346A1

公开(公告)日：2019-10-17

申请号：US16445913

申请日：2019-06-19

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Huji Turdi ,  Jon J. Hangeland ,  R. Michael Lawrence ,  Saleem Ahmad ,  Wei Meng ,  Robert Paul Brigance ,  Pratik Devasthale ,  Guohua Zhao

IPC: A61K31/438 ,  C07F9/59 ,  C07D401/10 ,  C07D401/14 ,  A61K31/5377 ,  C07D413/14 ,  C07D221/20 ,  C07D413/04 ,  A61K31/4439 ,  C07D401/04 ,  A61K31/4418 ,  C07D211/90 ,  A61K31/675 ,  C07D405/14 ,  C07F9/40 ,  C07F9/535 ,  C07D211/86 ,  C07D417/14 ,  C07D417/04 ,  C07D413/12 ,  C07D407/14 ,  C07D401/12 ,  A61K45/06

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

公开(公告)号：US20180133198A1

公开(公告)日：2018-05-17

申请号：US15867825

申请日：2018-01-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Huji Turdi ,  Jon J. Hangeland ,  R. Michael Lawrence ,  Saleem Ahmad ,  Wei Meng ,  Robert Paul Brigance ,  Pratik Devasthale ,  Guohua Zhao

IPC: A61K31/438 ,  C07F9/59 ,  A61K31/4418 ,  C07F9/40 ,  C07D417/14 ,  C07D417/04 ,  C07D413/14 ,  C07D413/12 ,  C07D413/04 ,  C07D407/14 ,  C07D405/14 ,  C07D401/14 ,  C07D401/12 ,  C07D401/10 ,  C07D401/04 ,  C07D221/20 ,  C07D211/90 ,  C07D211/86 ,  A61K45/06 ,  A61K31/675 ,  A61K31/5377 ,  A61K31/4439 ,  C07F9/535

CPC classification number: A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/5377 ,  A61K31/675 ,  A61K45/06 ,  C07D211/86 ,  C07D211/90 ,  C07D221/20 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07F9/4006 ,  C07F9/5352 ,  C07F9/59

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

公开(公告)号：US09586900B2

公开(公告)日：2017-03-07

申请号：US14425507

申请日：2013-09-03

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Saleem Ahmad ,  Guohua Zhao ,  William N. Washburn

IPC: C07D207/273 ,  C07D207/327 ,  C07D401/12 ,  C07D409/12 ,  A61K31/4015 ,  A61K31/4025 ,  A61K31/4439 ,  C07D403/12 ,  C07D207/27

CPC classification number: C07D207/273 ,  C07D207/27 ,  C07D207/327 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12

Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are melanin concentrating hormone receptor-1 (MCHR1) antagonists which may be used as medicaments.

Abstract translation: 本发明提供式（I）化合物：如说明书中所定义和包含任何这些新化合物的组合物。 这些化合物是可用作药物的黑色素浓缩激素受体-1（MCHR1）拮抗剂。

公开(公告)号：US20160031816A1

公开(公告)日：2016-02-04

申请号：US14883067

申请日：2015-10-14

Applicant: Bristol-Myers Squibb Company

Inventor： Huji Turdi ,  Jon J. Hangeland ,  R. Michael Lawrence ,  Dong Cheng ,  Saleem Ahmad ,  Wei Meng ,  Robert Paul Brigance ,  Pratik Devasthale ,  Guohua Zhao

IPC: C07D211/90 ,  C07D221/20 ,  C07D401/10 ,  C07D401/04 ,  C07D405/14 ,  C07D401/14 ,  C07D211/86 ,  C07D417/04 ,  C07D413/12 ,  C07D401/12 ,  C07D413/04

CPC classification number: A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/5377 ,  A61K31/675 ,  A61K45/06 ,  C07D211/86 ,  C07D211/90 ,  C07D221/20 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07F9/4006 ,  C07F9/5352 ,  C07F9/59

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

公开(公告)号：US08791091B2

公开(公告)日：2014-07-29

申请号：US13688584

申请日：2012-11-29

Applicant: Bristol-Myers Squibb Company

Inventor： Huji Turdi ,  Jon J. Hangeland ,  R. Michael Lawrence ,  Saleem Ahmad ,  Wei Meng ,  Robert Paul Brigance ,  Pratik Devasthale ,  Guohua Zhao

IPC: A61K31/675 ,  A61K31/4418 ,  A61K45/06 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/5377 ,  C07D401/04 ,  C07D413/04 ,  C07D413/14 ,  C07F9/59 ,  C07D401/14 ,  C07D211/90 ,  C07D221/20

CPC classification number: A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/5377 ,  A61K31/675 ,  A61K45/06 ,  C07D211/86 ,  C07D211/90 ,  C07D221/20 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07F9/4006 ,  C07F9/5352 ,  C07F9/59

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

Abstract translation: 本发明提供式（I）化合物或其立体异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是可用作药物的单酰基甘油酰基转移酶2型（MGAT2）抑制剂。

公开(公告)号：US10730863B2

公开(公告)日：2020-08-04

申请号：US16175895

申请日：2018-10-31

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： David S. Yoon ,  Rushith Kumar Anumula ,  Srinivas Cheruku ,  Yanting Huang ,  Elizabeth Anne Jurica ,  Wei Meng ,  Susheel Jethanand Nara ,  Rishikesh Narayan ,  Ramesh Kumar Sistla ,  Ximao Wu ,  Guohua Zhao

IPC: C07D413/14 ,  C07D413/04 ,  A61P35/00 ,  A61P29/00 ,  A61P13/12 ,  A61P1/16 ,  A61P1/18 ,  C07D261/08 ,  A61K31/428 ,  C07D417/14 ,  A61K31/4245 ,  C07D471/04 ,  A61K31/429 ,  A61K31/422 ,  C07D417/12

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US20190256512A1

公开(公告)日：2019-08-22

申请号：US16347826

申请日：2017-11-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guohua Zhao ,  James Mignone

IPC: C07D471/04 ,  A61P11/00 ,  A61P13/12 ,  A61P1/16 ,  A61P35/00

Abstract: The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US09901572B2

公开(公告)日：2018-02-27

申请号：US15488642

申请日：2017-04-17

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Huji Turdi ,  Jon J. Hangeland ,  R. Michael Lawrence ,  Saleem Ahmad ,  Wei Meng ,  Robert Paul Brigance ,  Pratik Devasthale ,  Guohua Zhao

IPC: C07D211/90 ,  C07D401/04 ,  A61K31/4439 ,  A61K31/438 ,  A61K31/675 ,  A61K31/4418 ,  C07D413/04 ,  C07D221/20 ,  C07D413/14 ,  A61K31/5377 ,  C07F9/59 ,  C07D401/14 ,  A61K45/06 ,  C07D401/10 ,  C07D401/12 ,  C07D407/14 ,  C07D413/12 ,  C07D417/04 ,  C07D417/14 ,  C07D211/86 ,  C07F9/535 ,  C07F9/40 ,  C07D405/14

CPC classification number: A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/5377 ,  A61K31/675 ,  A61K45/06 ,  C07D211/86 ,  C07D211/90 ,  C07D221/20 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07F9/4006 ,  C07F9/5352 ,  C07F9/59

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

公开(公告)号：US20170267666A1

公开(公告)日：2017-09-21

申请号：US15617079

申请日：2017-06-08

Applicant: Bristol-Myers Squibb Company

Inventor： Wei Meng ,  Guohua Zhao

IPC: C07D409/14 ,  C07D401/04 ,  C07D409/04 ,  C07D417/14 ,  A61K31/506 ,  A61K31/444 ,  A61K31/4439 ,  A61K31/4436 ,  C07D401/14 ,  A61K45/06

CPC classification number: C07D409/14 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/506 ,  A61K45/06 ,  C07D401/04 ,  C07D401/14 ,  C07D409/04 ,  C07D417/14

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

公开(公告)号：US11639353B2

公开(公告)日：2023-05-02

申请号：US17212210

申请日：2021-03-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pratik Devasthale ,  Fang Moore ,  Guohua Zhao ,  Susan Nicole Pieniazek ,  Kumaravel Selvakumar ,  Suresh Dhanusu ,  Manoranjan Panda ,  Lawrence R. Marcin

IPC: C07D471/04 ,  A61K31/4375 ,  A61P1/16 ,  A61P13/12 ,  A61P11/00 ,  A61P35/00

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.